BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 16720142)

  • 21. Port site and distant metastases of gallbladder cancer after laparoscopic cholecystectomy diagnosed by positron emission tomography.
    Hu JB; Sun XN; Xu J; He C
    World J Gastroenterol; 2008 Nov; 14(41):6428-31. PubMed ID: 19009666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of PET/CT for the differentiation and characterization of periampullary lesions.
    Cheng MF; Wang HP; Tien YW; Liu KL; Yen RF; Tzen KY; Wu YW
    Clin Nucl Med; 2013 Sep; 38(9):703-8. PubMed ID: 23816944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
    Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
    HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
    Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
    J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of
    Wen G; Gu J; Zhou W; Wang L; Tian Y; Dong Y; Fu L; Wu H
    Eur Radiol; 2020 Sep; 30(9):5089-5098. PubMed ID: 32346795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms.
    Sperti C; Pasquali C; Fiore V; Bissoli S; Chierichetti F; Liessi G; Pedrazzoli S
    Am J Surg; 2006 Jun; 191(6):743-8. PubMed ID: 16720142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
    Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic signatures of malignant and non-malignant mass-forming lesions in the periampulla and pancreas in FDG PET/CT scan: an atlas with pathologic correlation.
    Santhosh S; Mittal BR; Rana SS; Srinivasan R; Bhattacharya A; Das A; Bhasin D
    Abdom Imaging; 2015 Jun; 40(5):1285-315. PubMed ID: 25296997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
    Buchmann I; Ganten TM; Haberkorn U
    Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma.
    Moon CM; Bang S; Chung JB
    Surg Oncol; 2011 Mar; 20(1):e10-7. PubMed ID: 19804967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staging and follow-up of gastrointestinal tumors with PET/CT.
    Rosenbaum SJ; Stergar H; Antoch G; Veit P; Bockisch A; Kühl H
    Abdom Imaging; 2006; 31(1):25-35. PubMed ID: 16333707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.